Propofol versus placebo

Background One major limitation for less invasive surfactant administration (LISA) is the difficulty in providing sedation before this procedure and the competitive risk of respiratory depression versus avoidance of intubation for most sedative or analgesic drugs used in this context. The objective...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BMC pediatrics 2020-05, Vol.20 (1)
Hauptverfasser: Chevallier, Marie, Durrmeyer, Xavier, Ego, Anne, Debillon, Thierry, Beuchee, Alain, Bourgoin, Laura, Desenfants, Aurélie, Durandy, Amélie, Flamant, Cyril, Gascoin, Géraldine, Ghostine, Ghida, Parra, Johanna, Ponthier, Laure, Roué, Jean-Michel
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 1
container_start_page
container_title BMC pediatrics
container_volume 20
creator Chevallier, Marie
Durrmeyer, Xavier
Ego, Anne
Debillon, Thierry
Beuchee, Alain
Bourgoin, Laura
Desenfants, Aurélie
Durandy, Amélie
Flamant, Cyril
Gascoin, Géraldine
Ghostine, Ghida
Parra, Johanna
Ponthier, Laure
Roué, Jean-Michel
description Background One major limitation for less invasive surfactant administration (LISA) is the difficulty in providing sedation before this procedure and the competitive risk of respiratory depression versus avoidance of intubation for most sedative or analgesic drugs used in this context. The objective of this study is to compare the need for mechanical ventilation within 72 h of life following premedication with propofol, versus placebo (rescue with ketamine), for the LISA procedure in preterm neonates born before 32 weeks gestational age (wGA). Methods ProLISA is a phase III, non-inferiority, multicenter, double blind, randomized, placebo controlled trial designed according to the SPIRIT Statement. Neonates born before 32 wGA in 12 geographically dispersed Neonatal Intensive Care Units in France needing surfactant will be included from September 2019 to September 2022. A sample of 542 patients is needed. The neonate is randomized to the intervention (propofol) or control placebo group. Open label rescue treatment with ketamine is possible in both groups if FANS (Faceless Acute Neonatal pain Scale) is [greater than or equai to]6. To guide drug administration, FANS is scored before attempting laryngoscopy. Once an adequate score has been obtained, LISA is performed according to a standardized protocol. The primary outcome is the need for mechanical ventilation within 72 h of life. Secondary outcomes are tolerance of the procedure, pain evaluation, hemodynamic and neurologic parameters after the intervention, morbidities before discharge and neurodevelopmental assessment at 2 years of age. Discussion This paper describes the first multicenter, double-blind, randomized, placebo-controlled trial on this topic and will provide crucial information to support implementation of the LISA procedure. Trial registration ClinicalTrials.gov: NCT04016246. Registered 06 June 2019, N[degrees]EUDRACT: 2018-002876-41. Keywords: Less invasive surfactant administration, Sedation, Propofol, Ketamine, Randomized study
doi_str_mv 10.1186/s12887-020-02112-x
format Article
fullrecord <record><control><sourceid>gale</sourceid><recordid>TN_cdi_gale_infotracmisc_A627443571</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A627443571</galeid><sourcerecordid>A627443571</sourcerecordid><originalsourceid>FETCH-LOGICAL-g671-c6dd18cfe16eba21c37877a102c214a427d3e9be635a996ccd913b590910510d3</originalsourceid><addsrcrecordid>eNptTE1LAzEUDMWCtfYseCp4Ts1Lsvk4lqJVKOih95J9eSlbtk3ZqPjzDeihBxmGGYaZYewexALAmccC0jnLhRSVAJJ_j9gEtAUutYKrC3_Nbko5CAHWaTNhd-9DPueU-_kXDeWzzM99QGrzLRun0Bea_emUbZ-ftqsXvnlbv66WG7439RBNjOAwERhqgwRU1lkbQEiUoIOWNiryLRnVBO8NYvSg2sYLD6IBEdWUPfze7kNPu-6U8scQ8NgV3C2NtFqrxkJtLf5pVUQ6dphPlLqaXwx-AEYzS4U</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Propofol versus placebo</title><source>DOAJ Directory of Open Access Journals</source><source>SpringerLink Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><source>Springer Nature OA Free Journals</source><creator>Chevallier, Marie ; Durrmeyer, Xavier ; Ego, Anne ; Debillon, Thierry ; Beuchee, Alain ; Bourgoin, Laura ; Desenfants, Aurélie ; Durandy, Amélie ; Flamant, Cyril ; Gascoin, Géraldine ; Ghostine, Ghida ; Parra, Johanna ; Ponthier, Laure ; Roué, Jean-Michel</creator><creatorcontrib>Chevallier, Marie ; Durrmeyer, Xavier ; Ego, Anne ; Debillon, Thierry ; Beuchee, Alain ; Bourgoin, Laura ; Desenfants, Aurélie ; Durandy, Amélie ; Flamant, Cyril ; Gascoin, Géraldine ; Ghostine, Ghida ; Parra, Johanna ; Ponthier, Laure ; Roué, Jean-Michel</creatorcontrib><description>Background One major limitation for less invasive surfactant administration (LISA) is the difficulty in providing sedation before this procedure and the competitive risk of respiratory depression versus avoidance of intubation for most sedative or analgesic drugs used in this context. The objective of this study is to compare the need for mechanical ventilation within 72 h of life following premedication with propofol, versus placebo (rescue with ketamine), for the LISA procedure in preterm neonates born before 32 weeks gestational age (wGA). Methods ProLISA is a phase III, non-inferiority, multicenter, double blind, randomized, placebo controlled trial designed according to the SPIRIT Statement. Neonates born before 32 wGA in 12 geographically dispersed Neonatal Intensive Care Units in France needing surfactant will be included from September 2019 to September 2022. A sample of 542 patients is needed. The neonate is randomized to the intervention (propofol) or control placebo group. Open label rescue treatment with ketamine is possible in both groups if FANS (Faceless Acute Neonatal pain Scale) is [greater than or equai to]6. To guide drug administration, FANS is scored before attempting laryngoscopy. Once an adequate score has been obtained, LISA is performed according to a standardized protocol. The primary outcome is the need for mechanical ventilation within 72 h of life. Secondary outcomes are tolerance of the procedure, pain evaluation, hemodynamic and neurologic parameters after the intervention, morbidities before discharge and neurodevelopmental assessment at 2 years of age. Discussion This paper describes the first multicenter, double-blind, randomized, placebo-controlled trial on this topic and will provide crucial information to support implementation of the LISA procedure. Trial registration ClinicalTrials.gov: NCT04016246. Registered 06 June 2019, N[degrees]EUDRACT: 2018-002876-41. Keywords: Less invasive surfactant administration, Sedation, Propofol, Ketamine, Randomized study</description><identifier>ISSN: 1471-2431</identifier><identifier>EISSN: 1471-2431</identifier><identifier>DOI: 10.1186/s12887-020-02112-x</identifier><language>eng</language><publisher>BioMed Central Ltd</publisher><subject>Analgesics ; Clinical trials ; Neonatal intensive care ; Phenols (Class of compounds) ; Premature infants ; Propofol ; Surface active agents</subject><ispartof>BMC pediatrics, 2020-05, Vol.20 (1)</ispartof><rights>COPYRIGHT 2020 BioMed Central Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,860,27901,27902</link.rule.ids></links><search><creatorcontrib>Chevallier, Marie</creatorcontrib><creatorcontrib>Durrmeyer, Xavier</creatorcontrib><creatorcontrib>Ego, Anne</creatorcontrib><creatorcontrib>Debillon, Thierry</creatorcontrib><creatorcontrib>Beuchee, Alain</creatorcontrib><creatorcontrib>Bourgoin, Laura</creatorcontrib><creatorcontrib>Desenfants, Aurélie</creatorcontrib><creatorcontrib>Durandy, Amélie</creatorcontrib><creatorcontrib>Flamant, Cyril</creatorcontrib><creatorcontrib>Gascoin, Géraldine</creatorcontrib><creatorcontrib>Ghostine, Ghida</creatorcontrib><creatorcontrib>Parra, Johanna</creatorcontrib><creatorcontrib>Ponthier, Laure</creatorcontrib><creatorcontrib>Roué, Jean-Michel</creatorcontrib><title>Propofol versus placebo</title><title>BMC pediatrics</title><description>Background One major limitation for less invasive surfactant administration (LISA) is the difficulty in providing sedation before this procedure and the competitive risk of respiratory depression versus avoidance of intubation for most sedative or analgesic drugs used in this context. The objective of this study is to compare the need for mechanical ventilation within 72 h of life following premedication with propofol, versus placebo (rescue with ketamine), for the LISA procedure in preterm neonates born before 32 weeks gestational age (wGA). Methods ProLISA is a phase III, non-inferiority, multicenter, double blind, randomized, placebo controlled trial designed according to the SPIRIT Statement. Neonates born before 32 wGA in 12 geographically dispersed Neonatal Intensive Care Units in France needing surfactant will be included from September 2019 to September 2022. A sample of 542 patients is needed. The neonate is randomized to the intervention (propofol) or control placebo group. Open label rescue treatment with ketamine is possible in both groups if FANS (Faceless Acute Neonatal pain Scale) is [greater than or equai to]6. To guide drug administration, FANS is scored before attempting laryngoscopy. Once an adequate score has been obtained, LISA is performed according to a standardized protocol. The primary outcome is the need for mechanical ventilation within 72 h of life. Secondary outcomes are tolerance of the procedure, pain evaluation, hemodynamic and neurologic parameters after the intervention, morbidities before discharge and neurodevelopmental assessment at 2 years of age. Discussion This paper describes the first multicenter, double-blind, randomized, placebo-controlled trial on this topic and will provide crucial information to support implementation of the LISA procedure. Trial registration ClinicalTrials.gov: NCT04016246. Registered 06 June 2019, N[degrees]EUDRACT: 2018-002876-41. Keywords: Less invasive surfactant administration, Sedation, Propofol, Ketamine, Randomized study</description><subject>Analgesics</subject><subject>Clinical trials</subject><subject>Neonatal intensive care</subject><subject>Phenols (Class of compounds)</subject><subject>Premature infants</subject><subject>Propofol</subject><subject>Surface active agents</subject><issn>1471-2431</issn><issn>1471-2431</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNptTE1LAzEUDMWCtfYseCp4Ts1Lsvk4lqJVKOih95J9eSlbtk3ZqPjzDeihBxmGGYaZYewexALAmccC0jnLhRSVAJJ_j9gEtAUutYKrC3_Nbko5CAHWaTNhd-9DPueU-_kXDeWzzM99QGrzLRun0Bea_emUbZ-ftqsXvnlbv66WG7439RBNjOAwERhqgwRU1lkbQEiUoIOWNiryLRnVBO8NYvSg2sYLD6IBEdWUPfze7kNPu-6U8scQ8NgV3C2NtFqrxkJtLf5pVUQ6dphPlLqaXwx-AEYzS4U</recordid><startdate>20200508</startdate><enddate>20200508</enddate><creator>Chevallier, Marie</creator><creator>Durrmeyer, Xavier</creator><creator>Ego, Anne</creator><creator>Debillon, Thierry</creator><creator>Beuchee, Alain</creator><creator>Bourgoin, Laura</creator><creator>Desenfants, Aurélie</creator><creator>Durandy, Amélie</creator><creator>Flamant, Cyril</creator><creator>Gascoin, Géraldine</creator><creator>Ghostine, Ghida</creator><creator>Parra, Johanna</creator><creator>Ponthier, Laure</creator><creator>Roué, Jean-Michel</creator><general>BioMed Central Ltd</general><scope/></search><sort><creationdate>20200508</creationdate><title>Propofol versus placebo</title><author>Chevallier, Marie ; Durrmeyer, Xavier ; Ego, Anne ; Debillon, Thierry ; Beuchee, Alain ; Bourgoin, Laura ; Desenfants, Aurélie ; Durandy, Amélie ; Flamant, Cyril ; Gascoin, Géraldine ; Ghostine, Ghida ; Parra, Johanna ; Ponthier, Laure ; Roué, Jean-Michel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g671-c6dd18cfe16eba21c37877a102c214a427d3e9be635a996ccd913b590910510d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Analgesics</topic><topic>Clinical trials</topic><topic>Neonatal intensive care</topic><topic>Phenols (Class of compounds)</topic><topic>Premature infants</topic><topic>Propofol</topic><topic>Surface active agents</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chevallier, Marie</creatorcontrib><creatorcontrib>Durrmeyer, Xavier</creatorcontrib><creatorcontrib>Ego, Anne</creatorcontrib><creatorcontrib>Debillon, Thierry</creatorcontrib><creatorcontrib>Beuchee, Alain</creatorcontrib><creatorcontrib>Bourgoin, Laura</creatorcontrib><creatorcontrib>Desenfants, Aurélie</creatorcontrib><creatorcontrib>Durandy, Amélie</creatorcontrib><creatorcontrib>Flamant, Cyril</creatorcontrib><creatorcontrib>Gascoin, Géraldine</creatorcontrib><creatorcontrib>Ghostine, Ghida</creatorcontrib><creatorcontrib>Parra, Johanna</creatorcontrib><creatorcontrib>Ponthier, Laure</creatorcontrib><creatorcontrib>Roué, Jean-Michel</creatorcontrib><jtitle>BMC pediatrics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chevallier, Marie</au><au>Durrmeyer, Xavier</au><au>Ego, Anne</au><au>Debillon, Thierry</au><au>Beuchee, Alain</au><au>Bourgoin, Laura</au><au>Desenfants, Aurélie</au><au>Durandy, Amélie</au><au>Flamant, Cyril</au><au>Gascoin, Géraldine</au><au>Ghostine, Ghida</au><au>Parra, Johanna</au><au>Ponthier, Laure</au><au>Roué, Jean-Michel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Propofol versus placebo</atitle><jtitle>BMC pediatrics</jtitle><date>2020-05-08</date><risdate>2020</risdate><volume>20</volume><issue>1</issue><issn>1471-2431</issn><eissn>1471-2431</eissn><abstract>Background One major limitation for less invasive surfactant administration (LISA) is the difficulty in providing sedation before this procedure and the competitive risk of respiratory depression versus avoidance of intubation for most sedative or analgesic drugs used in this context. The objective of this study is to compare the need for mechanical ventilation within 72 h of life following premedication with propofol, versus placebo (rescue with ketamine), for the LISA procedure in preterm neonates born before 32 weeks gestational age (wGA). Methods ProLISA is a phase III, non-inferiority, multicenter, double blind, randomized, placebo controlled trial designed according to the SPIRIT Statement. Neonates born before 32 wGA in 12 geographically dispersed Neonatal Intensive Care Units in France needing surfactant will be included from September 2019 to September 2022. A sample of 542 patients is needed. The neonate is randomized to the intervention (propofol) or control placebo group. Open label rescue treatment with ketamine is possible in both groups if FANS (Faceless Acute Neonatal pain Scale) is [greater than or equai to]6. To guide drug administration, FANS is scored before attempting laryngoscopy. Once an adequate score has been obtained, LISA is performed according to a standardized protocol. The primary outcome is the need for mechanical ventilation within 72 h of life. Secondary outcomes are tolerance of the procedure, pain evaluation, hemodynamic and neurologic parameters after the intervention, morbidities before discharge and neurodevelopmental assessment at 2 years of age. Discussion This paper describes the first multicenter, double-blind, randomized, placebo-controlled trial on this topic and will provide crucial information to support implementation of the LISA procedure. Trial registration ClinicalTrials.gov: NCT04016246. Registered 06 June 2019, N[degrees]EUDRACT: 2018-002876-41. Keywords: Less invasive surfactant administration, Sedation, Propofol, Ketamine, Randomized study</abstract><pub>BioMed Central Ltd</pub><doi>10.1186/s12887-020-02112-x</doi></addata></record>
fulltext fulltext
identifier ISSN: 1471-2431
ispartof BMC pediatrics, 2020-05, Vol.20 (1)
issn 1471-2431
1471-2431
language eng
recordid cdi_gale_infotracmisc_A627443571
source DOAJ Directory of Open Access Journals; SpringerLink Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; PubMed Central Open Access; Springer Nature OA Free Journals
subjects Analgesics
Clinical trials
Neonatal intensive care
Phenols (Class of compounds)
Premature infants
Propofol
Surface active agents
title Propofol versus placebo
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T23%3A35%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Propofol%20versus%20placebo&rft.jtitle=BMC%20pediatrics&rft.au=Chevallier,%20Marie&rft.date=2020-05-08&rft.volume=20&rft.issue=1&rft.issn=1471-2431&rft.eissn=1471-2431&rft_id=info:doi/10.1186/s12887-020-02112-x&rft_dat=%3Cgale%3EA627443571%3C/gale%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A627443571&rfr_iscdi=true